Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Cellectis confirmed Servier's exclusive worldwide licensing option exercise for UCART19, triggering the milestone structure originally negotiated in February…
Cellectis CEO Andre Choulika told Fierce Biotech the 2014 Servier deal gave Cellectis 'validation and a bit of cash' at a moment when 'no one really believed…
BioPharma Dive recapped the Servier-Cellectis-Pfizer-Allogene chain, noting Servier's eventual exit reflected allogeneic CAR-T's failure to match autologous…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Servier paid Cellectis $10M upfront plus up to $140M per program in milestones across six allogeneic CAR-T candidates including lead UCART19 for B-cell leukemia. The pact was a precedent-setting bet on off-the-shelf gene-edited cell therapy and Servier later exercised its UCART19 option in November 2015.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Servier SAS / Cellectis SA (this deal) | 2014 | $850M | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2014 deals · Hematology deals